SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Sunset illuminating the tall skyscrapers of San Diego in California from Centennial Park in Coronado
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
 · 
5 min read
 · 
Nick Paul Taylor
FDA signage at its headquarters in Maryland
FDA
FDA mulls compounding for peptides previously flagged over safety risks
With Health Secretary Robert F. Kennedy Jr. declaring himself “a big fan of peptides,” the FDA has arranged an advisory committee to discuss allowing compounders to make molecules despite earlier safety concerns.
April 16, 2026
 · 
1 min read
 · 
Nick Paul Taylor
Globe and stack with coins. Money makes the world go round
Manufacturing
Lilly investing billions to prepare for overseas oral GLP-1 launches
With many overseas patients preferring orals to injectables, Eli Lilly has filed for approval of orforglipron in more than 40 countries and is building manufacturing capacity to support the obesity drug.
April 14, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Aerial view of cargo ship terminal
Manufacturing
USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns
Almost half of the top 100 medicines vulnerable to supply disruptions in the U.S. have at least one key starting material with a single source country, according to a new report from United States Pharmacopeia.
April 13, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Business teamwork and partnership help to achieve team success, think together to solve business problem, business connection concept, businessmen working team building connect jigsaw puzzle bridge.
FDA
FDA’s CRL transparency policy is boosting biopharma accountability
Since the FDA began publishing its rejections of drug approval filings in July last year, companies have become more forthcoming about the details of agency decisions in their own disclosures, according to biopharma and regulatory analysts.
April 13, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Chemistry creative concept. Circle frame with icons. Flag of China
Manufacturing
Innovent’s CDMO gets green light to make biologics at large Chinese plant
The license, which Innovent’s Altruist business said is the first of its kind, positions the CDMO to support commercial clients as it works to expand the plant’s capacity to 172,000 liters.
April 9, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Trendy halftone collage. Legislation concept, regulations, rules, law, authority, legal document, verdict. Hands holding a gavel with scales and regulation document. Vector illustration
FDA
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes.
April 7, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Vector illustration of a businessman unplugging polluted factory
Manufacturing
BioNTech Starts Shuttering Singapore mRNA Manufacturing Site Amid Pipeline Pivot
BioNTech envisioned the site making hundreds of millions of vaccines a year, but has since shifted its pipeline to other modalities while mRNA technology continues to face headwinds in the U.S.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Abstract financial chart with stock graph market.Vector illustration
Tariffs
Trump Hits Drugmakers With 100% Tariff but Carve-outs Soften the Blow
While some large companies could start paying the full tariff in 120 days, many products, including orphan drugs, cell and gene therapies, and antibody-drug conjugates, will enjoy exemptions that waive or greatly reduce the levies.
April 3, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Hands protect to stop rectangle block dominos with others rectangle standing. Risk and crisis management concept.
Vaccines
Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment
COVID-19 partners Pfizer and BioNTech have been unable to recruit healthy adults aged 50 to 64 fast enough to deliver relevant post-marketing data. Moderna is apparently also facing enrollment challenges.
April 2, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Novo Nordisk advertising flags and logo on facade
Layoffs
Layoffs at Novo’s Ex-Catalent Site Despite Signs of Turnaround, Continued Investment
As Novo Nordisk cuts 400 jobs at the troubled site, Scholar Rock has seen enough progress that it included the facility in a resubmission for FDA approval.
April 1, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Pills, capsules and tablets that shape the map of the world, as a symbol for global medicine issues. Vector illustration.
Drug pricing
Trump’s MFN Pricing Expected To Delay More European Drug Launches
Following Insmed’s decision to hold off on launching a newly approved lung disease drug in Europe, experts anticipate more companies will do the same as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the void?
April 1, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Pictured: Skyline of Atlanta
Manufacturing
UCB Investing $2B To Build Manufacturing Facility in Georgia
The Belgian drugmaker plans to hire about 330 people at a facility that will use advanced manufacturing technologies including AI, robotics and automation to meet rising demand for key products. This will be UCB’s first biologics manufacturing facility in the U.S.
March 25, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Microscopes, books and test tubes amidst colorful balls on a pink background.-3d rendering."n
FDA
FDA Blueprint Aims To Cut Regulatory Risk for Alternatives to Animal Testing
Draft guidance, issued by the FDA last week, could remove ambiguity and uncertainty that may have so far limited uptake of new approach methodologies, experts told BioSpace, particularly emphasizing the agency’s recommendations around defining NAMs’ regulatory purpose.
March 24, 2026
 · 
3 min read
 · 
Nick Paul Taylor
Symbolic image: Tablets, US Dollar and China - Dependence on the Chinese pharmaceutical industry
Manufacturing
Novartis Pledges $480M To Expand China Presence, Following Eli Lilly and AstraZeneca
Like its pharma peers, Novartis is pouring money into Chinese operations, including expansions and upgrades at an existing manufacturing facility.
March 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Load More